Bupivacaine

Evidence Level: L5

Predicted Indications: 4

Bupivacaine

Pharmacist Assessment Report

Bupivacaine: Amide local anesthetic (sodium channel blocker) → acrodermatitis chronica atrophicans

One-Sentence Summary

Bupivacaine is an amide local anesthetic that is marketed in Canada under multiple licences. The TxGNN model predicts it may be effective for acrodermatitis chronica atrophicans, with a score of 0.9923. There are currently no clinical trials and no publications supporting this direction, so the prediction rests on model output alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	acrodermatitis chronica atrophicans
TxGNN Prediction Score	0.9923
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 15 of 16; dormant: 1)
Number of DINs	16 (marketed: 15)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Bupivacaine is generally known as an amide local anesthetic that blocks voltage-gated sodium channels and thereby interrupts nerve conduction.

Acrodermatitis chronica atrophicans is the late skin manifestation of Borrelia infection, and its treatment relies on antibiotics. The only plausible role for bupivacaine is symptomatic relief of neuropathic pain, which is speculative. The high score reflects a model-based association, not a demonstrated mechanism, and no study cited here addresses this disease directly.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02241917	MARCAINE	–	–
02443694	BUPIVACAINE INJECTION BP	–	–
02460645	BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP	–	–
02512424	BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP	–	–
01976168	SENSORCAINE	–	–

All 16 licences are valid products; the five above are shown as examples.

Safety Considerations

Drug Interactions: 56 interactions were recorded. Those with a “Moderate” level are aprepitant and liposomal morphine. Others, such as pantoprazole, omeprazole, vancomycin, atropine, and several corticosteroids (prednisone, hydrocortisone, dexamethasone), have an unclassified severity level.
Conditions flagged as contraindications in the compiled data (not taken from label text): hypertension, liver failure and liver disease, kidney disease, epilepsy, COPD, respiratory failure, coronary artery disease, myocardial infarction, atrial fibrillation, heart conduction disease, sudden cardiac arrest, diabetes mellitus, hypothyroidism, inflammatory bowel disease, angle-closure glaucoma, and others.
Bupivacaine is myotoxic at high concentrations, and neonates are at added risk of systemic local anesthetic toxicity.

Please also refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has no supporting trials or publications, and the proposed mechanism is speculative. The disease is an infection that needs antibiotic treatment, so bupivacaine has no clear disease-modifying role.

To proceed, the following is needed:

Published or registered studies that directly address this disease
Mechanism of action data and a clear mechanistic rationale
Package insert warnings and contraindications from Health Canada
A defined route of administration and a safety review for the target population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.